BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30692274)

  • 1. Identification of Candidate Plasma Protein Biomarkers for Cervical Cancer Using the Multiplex Proximity Extension Assay.
    Berggrund M; Enroth S; Lundberg M; Assarsson E; Stålberg K; Lindquist D; Hallmans G; Grankvist K; Olovsson M; Gyllensten U
    Mol Cell Proteomics; 2019 Apr; 18(4):735-743. PubMed ID: 30692274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus DNA in plasma of patients with HPV16 DNA-positive uterine cervical cancer.
    Shimada T; Yamaguchi N; Nishida N; Yamasaki K; Miura K; Katamine S; Masuzaki H
    Jpn J Clin Oncol; 2010 May; 40(5):420-4. PubMed ID: 20133337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Triage of Premalignant Lesions in Liquid-Based Cervical Cytology and Circulating Cell-Free DNA from Urine, Using a Panel of Methylated Human Papilloma Virus and Host Genes.
    Guerrero-Preston R; Valle BL; Jedlicka A; Turaga N; Folawiyo O; Pirini F; Lawson F; Vergura A; Noordhuis M; Dziedzic A; Pérez G; Renehan M; Guerrero-Diaz C; De Jesus Rodríguez E; Diaz-Montes T; Rodríguez Orengo J; Méndez K; Romaguera J; Trock BJ; Florea L; Sidransky D
    Cancer Prev Res (Phila); 2016 Dec; 9(12):915-924. PubMed ID: 27671338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals.
    Thorsen SB; Lundberg M; Villablanca A; Christensen SL; Belling KC; Nielsen BS; Knowles M; Gee N; Nielsen HJ; Brünner N; Christensen IJ; Fredriksson S; Stenvang J; Assarsson E
    J Transl Med; 2013 Oct; 11():253. PubMed ID: 24107468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I.
    Wu R; Belinson SE; Du H; Na W; Qu X; Wu R; Liu Y; Wang C; Zhou Y; Zhang L; Belinson JL
    Int J Gynecol Cancer; 2010 Nov; 20(8):1411-4. PubMed ID: 21051986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can Genomic Amplification of Human Telomerase Gene and C-MYC in Liquid-Based Cytological Specimens Be Used as a Method for Opportunistic Cervical Cancer Screening?
    Gao K; Eurasian M; Zhang J; Wei Y; Zheng Q; Ye H; Li L
    Gynecol Obstet Invest; 2015; 80(3):153-63. PubMed ID: 25832290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Makorin Ring Finger Protein 1 as Adjunctive Marker in Liquid-based Cervical Cytology.
    Lee M; Chang MY; Shin HY; Shin E; Hong SW; Kim KM; Chay DB; Cho H; Kim JH
    Medicine (Baltimore); 2016 Jan; 95(3):e2425. PubMed ID: 26817873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the sensitivity and specificity of p16/Ki-67 dual staining and HPV DNA testing of abnormal cervical cytology in the detection of histology proven cervical intraepithelial neoplasia grade 2 and above (CIN 2+).
    Tay TKY; Lim KL; Hilmy MH; Thike AA; Goh ST; Song LH; Hwang JSG; Mantoo S
    Malays J Pathol; 2017 Dec; 39(3):257-265. PubMed ID: 29279588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytology versus HPV testing for cervical cancer screening in the general population.
    Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
    Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
    BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.
    Agorastos T; Chatzistamatiou K; Katsamagkas T; Koliopoulos G; Daponte A; Constantinidis T; Constantinidis TC;
    PLoS One; 2015; 10(3):e0119755. PubMed ID: 25793281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings.
    Kuhn L; Denny L; Pollack A; Lorincz A; Richart RM; Wright TC
    J Natl Cancer Inst; 2000 May; 92(10):818-25. PubMed ID: 10814677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women.
    Duvlis S; Popovska-Jankovic K; Arsova ZS; Memeti S; Popeska Z; Plaseska-Karanfilska D
    J Med Virol; 2015 Sep; 87(9):1578-86. PubMed ID: 25880030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program.
    Ovestad IT; Dalen I; Hansen E; Loge JL; Dybdahl BM; Dirdal MB; Moltu P; Berland JM
    Cancer Cytopathol; 2017 Apr; 125(4):283-291. PubMed ID: 27918650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
    Katki HA; Kinney WK; Fetterman B; Lorey T; Poitras NE; Cheung L; Demuth F; Schiffman M; Wacholder S; Castle PE
    Lancet Oncol; 2011 Jul; 12(7):663-72. PubMed ID: 21684207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical value of p16
    Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
    Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of molecular biomarker human papilloma virus (HPV) E6 oncoprotein in cervical cancer screening.
    Ara R; Khatun S; Pervin S; Jahan M; Shahera U; Ferdous J; Begum SA; Fatema S; Begum M; Nazneen S; Goodman A
    Gynecol Oncol; 2020 Sep; 158(3):590-596. PubMed ID: 32680634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.